Literature DB >> 15910494

Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B.

Chih-Lin Lin1, Li-Ying Liao, Chaur-Shine Wang, Pei-Jer Chen, Ming-Yang Lai, Ding-Shinn Chen, Jia-Horng Kao.   

Abstract

BACKGROUND/AIMS: The long-term outcomes in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are distinct from those in HBeAg-positive chronic hepatitis. However, the molecular virological factors that contribute to the progression of liver disease in this special clinical setting remain largely unknown. We thus investigated the association of hepatitis B virus (HBV) genotypes as well as precore/basal core-promoter mutations with the clinical and virological characteristics of patients with HBeAg-negative chronic hepatitis B in Taiwan.
METHODS: HBV genotypes and sequences of precore and basal core-promoter regions of the HBV genome were determined in 174 HBeAg-negative chronic HBV infection patients including 62 inactive carriers and 112 with different stages of liver disease.
RESULTS: HBV carriers with older age (> 50 years) (odds ratio, 9.09; 95% confidence interval (CI), 3.22-25, P < 0.001) and basal core-promoter mutant of HBV (odds ratio, 4.12; 95% CI, 1.41-12.03, P = 0.01) were associated with the development of liver cirrhosis and hepatocellular carcinoma (HCC). The gender-related risk factors associated with the development of liver cirrhosis and HCC were further analyzed, and basal core-promoter mutant was only associated with the development of liver cirrhosis and HCC in male carriers (odds ratio, 4.35; 95% CI, 1.30-14.52, P = 0.02).
CONCLUSIONS: The risk of development of liver cirrhosis and HCC is significantly increased in patients with advanced age as well as with basal core-promoter mutant of HBV. In addition, basal core-promoter mutant might contribute to the gender difference of the progression of liver disease in HBeAg-negative chronic hepatitis B in Taiwan.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15910494     DOI: 10.1111/j.1478-3231.2005.01041.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  22 in total

Review 1.  Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance.

Authors:  Catherine Mn Croagh; Paul V Desmond; Sally J Bell
Journal:  World J Hepatol       Date:  2015-03-27

2.  Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment.

Authors:  Juanjuan Zhao; Zheng Zhang; Yan Luan; Zhengsheng Zou; Yanling Sun; Yonggang Li; Lei Jin; Chunbao Zhou; Junliang Fu; Bin Gao; Yangxin Fu; Fu-Sheng Wang
Journal:  Hepatology       Date:  2014-03-01       Impact factor: 17.425

3.  HBx-K130M/V131I Promotes Liver Cancer in Transgenic Mice via AKT/FOXO1 Signaling Pathway and Arachidonic Acid Metabolism.

Authors:  Amy P Chiu; Barbara R Tschida; Tung-Ting Sham; Lilian H Lo; Branden S Moriarity; Xiao-Xiao Li; Regina C Lo; David E Hinton; Dewi K Rowlands; Chi-On Chan; Daniel K W Mok; David A Largaespada; Nadia Warner; Vincent W Keng
Journal:  Mol Cancer Res       Date:  2019-04-11       Impact factor: 5.852

4.  Role of viral factors in the natural course and therapy of chronic hepatitis B.

Authors:  Jia-Horng Kao
Journal:  Hepatol Int       Date:  2007-10-12       Impact factor: 6.047

Review 5.  Viral hepatitis B: clinical and epidemiological characteristics.

Authors:  Gregory S Burns; Alexander J Thompson
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-30       Impact factor: 6.915

6.  Genetic analysis of complement component 9 (C9) polymorphisms with clearance of hepatitis B virus infection.

Authors:  Joon Seol Bae; Charisse Flerida A Pasaje; Byung Lae Park; Hyun Sub Cheong; Jeong-Hyun Kim; Tae Joon Park; Jason Yongha Kim; Jin Sol Lee; In Song Koh; Hyo-Suk Lee; Yoon Jun Kim; Hyoung Doo Shin
Journal:  Dig Dis Sci       Date:  2011-03-05       Impact factor: 3.199

7.  Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: a prospective study.

Authors:  Chunping Wang; Yinying Lu; Yan Chen; Yongyi Feng; Linjing An; Xinzhen Wang; Shuhui Su; Wenlin Bai; Lin Zhou; Yongping Yang; Dongping Xu
Journal:  Clin Exp Metastasis       Date:  2009       Impact factor: 5.150

8.  HBV A1762T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study.

Authors:  Zhong-Liao Fang; Caroline A Sabin; Bai-Qing Dong; Lian-Ying Ge; Shao-Chao Wei; Qin-Yan Chen; Kong-Xiong Fang; Jin-Ye Yang; Xue-Yan Wang; Tim J Harrison
Journal:  Am J Gastroenterol       Date:  2008-09       Impact factor: 10.864

9.  Comparison of complete sequences of hepatitis B virus genotype C between inactive carriers and hepatocellular carcinoma patients before and after seroconversion.

Authors:  Kiyoaki Ito; Yasuhito Tanaka; Michio Kato; Kei Fujiwara; Fuminaka Sugauchi; Tomoyuki Sakamoto; Noboru Shinkai; Etsuro Orito; Masashi Mizokami
Journal:  J Gastroenterol       Date:  2007-10-15       Impact factor: 7.527

Review 10.  Hepatitis B virus variants.

Authors:  Watcharasak Chotiyaputta; Anna S F Lok
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-07-07       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.